Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years

Trial Profile

A Phase III Multicenter,Randomized Study Comparing Consolidation With 90yttrium-Labeled Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Vs Autologous Stem Cell Transplantation (ASCT) in Patients With Relapsed/Refractory Follicular Lymphoma (FL) Aged 18-65 Years

Recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jan 2019

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Bendamustine; Carboplatin; Carmustine; Cisplatin; Cyclophosphamide; Cytarabine; Dexamethasone; Doxorubicin; Epirubicin; Etoposide; Filgrastim; Fludarabine; Fotemustine; Ifosfamide; Lenograstim; Melphalan; Mitoxantrone; Prednisone; Rituximab; Vincristine
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-FLAZ-12
  • Most Recent Events

    • 27 Dec 2018 Planned End Date changed from 1 Apr 2019 to 1 Jan 2022.
    • 27 Dec 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jan 2020.
    • 18 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top